MX2020006641A - Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol. - Google Patents
Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol.Info
- Publication number
- MX2020006641A MX2020006641A MX2020006641A MX2020006641A MX2020006641A MX 2020006641 A MX2020006641 A MX 2020006641A MX 2020006641 A MX2020006641 A MX 2020006641A MX 2020006641 A MX2020006641 A MX 2020006641A MX 2020006641 A MX2020006641 A MX 2020006641A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrimidinyl
- preparation
- compounds
- lrrk2
- aminopyrazole compounds
- Prior art date
Links
- YLLPAAYZOKXPDB-UHFFFAOYSA-N 5-pyrimidin-2-yl-1h-pyrazol-4-amine Chemical class NC1=CNN=C1C1=NC=CC=N1 YLLPAAYZOKXPDB-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 abstract 2
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 2
- 229940124786 LRRK2 inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Abstract
La presente descripción se refiere a métodos para elaborar compuestos de pirimidinil-4- aminopirazol que inhiben LRRK2 e intermedios de fórmulas I y IV: Los compuestos son útiles como inhibidores de LRRK2 en el tratamiento de enfermedades mediadas por LRRK2 y como intermedios para su fabricación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608398P | 2017-12-20 | 2017-12-20 | |
| PCT/US2018/066595 WO2019126383A1 (en) | 2017-12-20 | 2018-12-19 | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006641A true MX2020006641A (es) | 2021-01-08 |
Family
ID=66994244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006641A MX2020006641A (es) | 2017-12-20 | 2018-12-19 | Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11834438B2 (es) |
| EP (1) | EP3727377B1 (es) |
| JP (1) | JP7284172B2 (es) |
| KR (1) | KR20200100757A (es) |
| CN (1) | CN112088003B (es) |
| AU (1) | AU2018392599A1 (es) |
| BR (1) | BR112020012611A2 (es) |
| CA (1) | CA3086182A1 (es) |
| IL (1) | IL275480B2 (es) |
| MA (1) | MA51339A (es) |
| MX (1) | MX2020006641A (es) |
| SG (1) | SG11202005752PA (es) |
| WO (1) | WO2019126383A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR118641A1 (es) * | 2019-04-11 | 2021-10-20 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| CN115894456A (zh) * | 2022-11-13 | 2023-04-04 | 药康众拓(江苏)医药科技有限公司 | 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2574168B9 (en) | 2010-05-21 | 2016-10-05 | Incyte Holdings Corporation | Topical formulation for a jak inhibitor |
| CA2797947C (en) | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| HUE037844T2 (hu) | 2010-11-10 | 2018-09-28 | Genentech Inc | Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| US8791130B2 (en) | 2011-11-29 | 2014-07-29 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 modulators |
| CA2850594C (en) | 2011-11-29 | 2020-03-10 | F. Hoffmann-La Roche Ag | Aminopyrimidine derivatives as lrrk2 modulators |
| ES2638595T3 (es) | 2011-11-29 | 2017-10-23 | Genentech, Inc. | Derivados de aminopirimidina como moduladores de LRRK2 |
| BR112014012822A8 (pt) | 2011-11-30 | 2017-07-11 | Hoffmann La Roche | Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2 |
| CN106279202A (zh) | 2012-05-03 | 2017-01-04 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物 |
| EP2844652B1 (en) | 2012-05-03 | 2019-03-13 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| US9238644B2 (en) * | 2012-08-17 | 2016-01-19 | Cancer Therapeutics Crc Pty Limited | VEGFR3 inhibitors |
| WO2017019804A2 (en) * | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2017087905A1 (en) * | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| CR20220182A (es) | 2016-06-16 | 2022-06-15 | Denali Therapeutics Inc | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos (divisional 2018-592) |
| US20200157081A1 (en) | 2017-05-24 | 2020-05-21 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| KR20200089713A (ko) | 2017-11-21 | 2020-07-27 | 데날리 테라퓨틱스 인크. | 피리미디닐아미노-피라졸 화합물의 다형체와 고체 형태, 그리고 생산 방법 |
| AR118641A1 (es) | 2019-04-11 | 2021-10-20 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
-
2018
- 2018-12-19 MX MX2020006641A patent/MX2020006641A/es unknown
- 2018-12-19 BR BR112020012611-0A patent/BR112020012611A2/pt unknown
- 2018-12-19 AU AU2018392599A patent/AU2018392599A1/en active Pending
- 2018-12-19 WO PCT/US2018/066595 patent/WO2019126383A1/en unknown
- 2018-12-19 SG SG11202005752PA patent/SG11202005752PA/en unknown
- 2018-12-19 EP EP18892459.1A patent/EP3727377B1/en active Active
- 2018-12-19 US US16/955,717 patent/US11834438B2/en active Active
- 2018-12-19 CN CN201880089536.1A patent/CN112088003B/zh active Active
- 2018-12-19 CA CA3086182A patent/CA3086182A1/en active Pending
- 2018-12-19 MA MA051339A patent/MA51339A/fr unknown
- 2018-12-19 IL IL275480A patent/IL275480B2/en unknown
- 2018-12-19 JP JP2020534236A patent/JP7284172B2/ja active Active
- 2018-12-19 KR KR1020207020841A patent/KR20200100757A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20210009566A1 (en) | 2021-01-14 |
| SG11202005752PA (en) | 2020-07-29 |
| KR20200100757A (ko) | 2020-08-26 |
| EP3727377B1 (en) | 2024-01-31 |
| EP3727377A4 (en) | 2021-08-18 |
| IL275480B1 (en) | 2023-06-01 |
| CN112088003B (zh) | 2023-10-13 |
| JP7284172B2 (ja) | 2023-05-30 |
| AU2018392599A1 (en) | 2020-07-09 |
| IL275480B2 (en) | 2023-10-01 |
| CA3086182A1 (en) | 2019-06-27 |
| IL275480A (en) | 2020-08-31 |
| MA51339A (fr) | 2020-10-28 |
| US11834438B2 (en) | 2023-12-05 |
| CN112088003A (zh) | 2020-12-15 |
| WO2019126383A1 (en) | 2019-06-27 |
| JP2021506892A (ja) | 2021-02-22 |
| EP3727377A1 (en) | 2020-10-28 |
| BR112020012611A2 (pt) | 2020-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501921A1 (en) | Novel compounds | |
| AU2017296095B2 (en) | Multispecific antibodies against CD40 and CD137 | |
| MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
| PH12018500057A1 (en) | Substituted oxopyridine derivatives | |
| PH12015501703A1 (en) | Trifluormethyl-substituted ring-fused pyrimidines and use thereof | |
| NZ758528A (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| TN2015000434A1 (en) | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | |
| AU2015237050A8 (en) | Quinoline derivatives as SMO inhibitors | |
| MY200744A (en) | Polypeptides antagonizing wnt signaling in tumor cells | |
| MX2021014663A (es) | Il-23a y tnf-alfa orientados y compuesto y sus usos. | |
| WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
| CA2878796C (en) | Derivatives of pyridinone as inhibitors for tissue transglutaminase | |
| EA201600096A1 (ru) | Бензил-1н-пиразол[3,4-b]пиридины и их применение | |
| EA201890572A1 (ru) | Биофармацевтические композиции | |
| PH12016500525A1 (en) | Substituted phenylalanine derivatives | |
| PH12017500595B1 (en) | Aldosterone synthase inhibitors | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MY191352A (en) | Aldosterone synthase inhibitors | |
| SG11201901973RA (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
| MX2020006641A (es) | Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol. | |
| MX365315B (es) | Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa. | |
| MX2019014272A (es) | Compuestos policiclicos y usos de los mismos. | |
| PH12015502650A1 (en) | Substituted benzoxazoles |